Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Liquidia Corporation Common Stock (LQDA) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance

Liquidia Corporation Common StockTrade
Vaxcyte Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Liquidia Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Liquidia Corporation Common Stock trades at $34.9 (market cap $2.40B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 4.4× Liquidia Corporation Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.

LQDAPCVX
Market Cap
$2.40B$10.51B
Volume
2,857,5472,644,694
Sector
HealthHealth
52-Week High
$91.03$73.82
52-Week Low
$22.02$40.32
Typical Hold Time
0 Days0 Days
Enterprise Value
$2.30B$9.14B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LQDA
62% Buy38% Sell
Avg holding period · 0 Days
PCVX
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Liquidia Corporation Common Stock

Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.

Read more on LQDA →

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →